Tagraxofusp in Combination with POM/DEX in Relapsed or Refractory Multiple Myeloma
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. ASH 2019. Poster
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp. ACR 2019. Poster
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). JSH 2019. Presentation
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). EHA 2019. POSTER
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. EHA 2019. POSTER
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2019. POSTER
CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are susceptible to the cytotoxic activity of tagraxofusp, a CD123-targeted therapy
CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are susceptible to the cytotoxic activity of tagraxofusp, a CD123-targeted therapy. EULAR 2019. POSTER
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). ASCO 2019. POSTER
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASCO 2019. POSTER
Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML). ASH 2018.
Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML). ASH 2018. POSTER